Get the Stockscreener App
21.73
1.92%
0.41
Elanco Animal Health Inc stock is traded at $21.73, with a volume of 5.83M.
It is up +1.92% in the last 24 hours and down -3.25% over the past month.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.
See More
Previous Close:
$21.32
Open:
$21.33
24h Volume:
5.83M
Relative Volume:
1.02
Market Cap:
$10.85B
Revenue:
$4.72B
Net Income/Loss:
$-232.00M
P/E Ratio:
-46.60
EPS:
-0.4663
Net Cash Flow:
$284.00M
1W Performance:
+9.42%
1M Performance:
-3.25%
6M Performance:
-2.34%
1Y Performance:
+71.51%
1-Day Range:
$21.30
$22.05
1-Week Range:
$19.40
$22.05
52-Week Range:
$12.40
$27.72
Elanco Animal Health Inc Stock (ELAN) Company Profile
Name
Elanco Animal Health Inc
Sector
Phone
877-352-6261
Address
450 ELANCO CIRCLE, INDIANAPOLIS
Compare ELAN vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELAN
Elanco Animal Health Inc
|
21.73 | 10.65B | 4.72B | -232.00M | 284.00M | -0.4663 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | Citigroup | Buy |
| Jan-22-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Nov-21-25 | Initiated | KeyBanc Capital Markets | Overweight |
| Nov-19-25 | Upgrade | Argus | Hold → Buy |
| Oct-07-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-17-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jun-26-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-09-24 | Initiated | UBS | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Market Perform |
| Sep-19-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-05-24 | Upgrade | Stifel | Hold → Buy |
| Dec-19-23 | Initiated | Jefferies | Buy |
| Dec-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-07-23 | Initiated | Exane BNP Paribas | Outperform |
| Apr-20-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-18-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-16-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-21-22 | Downgrade | Goldman | Buy → Sell |
| Jul-12-22 | Initiated | Piper Sandler | Neutral |
| Nov-18-21 | Initiated | Morgan Stanley | Overweight |
| Oct-28-21 | Downgrade | Stifel | Buy → Hold |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jun-15-21 | Upgrade | Cleveland Research | Underperform → Neutral |
| May-11-21 | Upgrade | Barclays | Underweight → Equal Weight |
| May-11-21 | Upgrade | Gabelli & Co | Hold → Buy |
| Apr-15-21 | Initiated | Stifel | Buy |
| Mar-22-21 | Downgrade | Gabelli & Co | Buy → Hold |
| Feb-26-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-09-20 | Downgrade | Argus | Buy → Hold |
| Nov-09-20 | Downgrade | Barclays | Overweight → Underweight |
| Aug-20-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-13-20 | Resumed | Credit Suisse | Neutral |
| Aug-04-20 | Resumed | Goldman | Buy |
| Jul-27-20 | Downgrade | Cleveland Research | Neutral → Underperform |
| Apr-02-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-20 | Initiated | Raymond James | Mkt Perform |
| Dec-19-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Nov-07-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-23-19 | Initiated | Barclays | Overweight |
| Aug-26-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-15-19 | Upgrade | UBS | Sell → Neutral |
| May-23-19 | Initiated | Guggenheim | Neutral |
| Mar-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Mar-13-19 | Resumed | Morgan Stanley | Equal-Weight |
| Feb-12-19 | Initiated | William Blair | Mkt Perform |
| Jan-23-19 | Initiated | UBS | Sell |
| Jan-15-19 | Initiated | Argus | Buy |
| Oct-15-18 | Initiated | Morgan Stanley | Equal-Weight |
View All
Elanco Animal Health Inc Stock (ELAN) Latest News
Q1 2026 Elanco Animal Health Inc Earnings Call Transcript - GuruFocus
Q1 Rundown: Elanco (NYSE:ELAN) Vs Other Pharmaceuticals Stocks - Yahoo Finance
ELAN Stock Price, Quote & Chart | ELANCO ANIMAL HEALTH INC (NYSE:ELAN) - ChartMill
Elanco Animal Health Inc Annual Shareholders Meeting Transcript - GuruFocus
Elanco Launches Befrena As New Dermatology Driver For Undervalued Shares - Yahoo Finance
Companion Animal Health Market is expected to Hit US$ 56.60 - openPR.com
Is Elanco Animal Health Inc (ELAN) Overvalued After 5.3% Rally? - GuruFocus
Elanco CEO Jeffrey Simmons buys $99,842 in company stock By Investing.com - Investing.com South Africa
Elanco EVP Rajeev Modi buys $99,938 of company stock By Investing.com - Investing.com South Africa
Elanco EVP Rajeev Modi buys $99,938 of company stock - Investing.com UK
Elanco CEO Jeffrey Simmons buys $99,842 in company stock - Investing.com UK
Elanco (NYSE: ELAN) officer Modi buys shares and receives deferred stock units - Stock Titan
Elanco (NYSE: ELAN) CEO adds shares and receives deferred units - Stock Titan
Elanco (NYSE: ELAN) CFO receives grant of deferred stock units as compensation - Stock Titan
Elanco Animal Health Launches Canine Dermatitis Drug Befrena - Moomoo
Elanco Animal Health (ELAN) 10K Form and Latest SEC Filings 2026 - MarketBeat
Elanco Animal Health’s SWOT analysis: stock outlook amid growth targets - Investing.com India
Elanco Animal Health’s SWOT analysis: stock outlook amid growth targets By Investing.com - Investing.com Nigeria
Elanco (ELAN) Launches New Canine Allergy Treatment Befrena - GuruFocus
Elanco launches canine dermatitis treatment Befrena in U.S. By Investing.com - Investing.com Canada
New dog allergy shot from Elanco offers 6–8 weeks of itch relief - Stock Titan
Elanco Animal Health (ELAN) Stock Report: A Healthcare Stock with Nearly 50% Upside Potential - DirectorsTalk Interviews
Elanco Q1 2026 Earnings: Revenue $1.37B, EPS $0.40, Guidance RaisedNews and Statistics - IndexBox
5 Insightful Analyst Questions From Elanco’s Q1 Earnings Call - Yahoo Finance
Elanco Animal Health Inc (ELAN) Shares Fall 8.2% -- What GF Scor - GuruFocus
Elanco Animal Health Inc (ELAN) Shares Fall 8.2% -- What GF Score of 70 Tells Investors - GuruFocus
Elanco finalizes acquisition of AHV International - Feed Strategy
Morgan Stanley Maintains Elanco Animal Health(ELAN.US) With Hold Rating, Raises Target Price to $23 - Moomoo
Elanco to Participate in Investor Conferences - Intellectia AI
Elanco to Participate in Upcoming Investor Conferences - GuruFocus
Dodge & Cox holds 13.9% of Elanco (NYSE: ELAN) in 13G/A amendment - Stock Titan
How to listen in as Elanco execs talk to investors in May and June - Stock Titan
Elanco reaches $9.3M settlement with consumers over antitrust allegations involving flea and tick products - Indianapolis Business Journal
Elanco to pay $6.75M to settle antitrust allegations involving flea and tick products - Inside INdiana Business
Primecap Management reports 9.22% stake in Elanco (ELAN) - Stock Titan
Elanco On Hook For Bulk Of $9M Flea & Tick Meds Deal - Law360
Earnings call transcript: Elanco Q1 2026 beats forecasts with strong growth - Investing.com Canada
Pet Wellness Products Market Touching New Development Level | Zoetis, Elanco, Virbac - openPR.com
Analysts Offer Insights on Healthcare Companies: Definitive Healthcare Corp (DH), Elanco Animal Health (ELAN) and Align Tech (ALGN) - The Globe and Mail
Elanco Animal Health Inc (ELAN) Shares Fall 8.2% -- GF Value Says Still Overvalued - GuruFocus
Elanco (ELAN) Q1 earnings: What to expect - MSN
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Elanco Animal Health - TMX Newsfile
Elanco Animal Health Q1 Earnings Call Highlights - MarketBeat
Q3 2025 Elanco Animal Health Inc Earnings Call Transcript - GuruFocus
Elanco Animal Health Inc Investor Day Transcript - GuruFocus
Elanco Animal Health Inc Stock (ELAN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.37%
4.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):